129 related articles for article (PubMed ID: 23561896)
1. Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9.
van Poelgeest EP; Swart RM; Betjes MG; Moerland M; Weening JJ; Tessier Y; Hodges MR; Levin AA; Burggraaf J
Am J Kidney Dis; 2013 Oct; 62(4):796-800. PubMed ID: 23561896
[TBL] [Abstract][Full Text] [Related]
2. Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial.
van Poelgeest EP; Hodges MR; Moerland M; Tessier Y; Levin AA; Persson R; Lindholm MW; Dumong Erichsen K; Ørum H; Cohen AF; Burggraaf J
Br J Clin Pharmacol; 2015 Dec; 80(6):1350-61. PubMed ID: 26261033
[TBL] [Abstract][Full Text] [Related]
3. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
4. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
[TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
Dragan S; Serban MC; Banach M
J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
7. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
8. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment.
Kwakernaak AJ; Lambert G; Slagman MC; Waanders F; Laverman GD; Petrides F; Dikkeschei BD; Navis G; Dullaart RP
Atherosclerosis; 2013 Feb; 226(2):459-65. PubMed ID: 23261172
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotides for the treatment of dyslipidaemia.
Visser ME; Witztum JL; Stroes ES; Kastelein JJ
Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
[TBL] [Abstract][Full Text] [Related]
10. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
[TBL] [Abstract][Full Text] [Related]
11. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
Jin K; Park BS; Kim YW; Vaziri ND
Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
[TBL] [Abstract][Full Text] [Related]
12. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
[TBL] [Abstract][Full Text] [Related]
13. Low levels of low-density lipoprotein-C associated with proprotein convertase subtilisin kexin 9 inhibition do not increase the risk of hemorrhagic transformation.
Tran-Dinh A; Levoye A; Lambert G; Louedec L; Journé C; Meilhac O; Amarenco P
Stroke; 2014 Oct; 45(10):3086-8. PubMed ID: 25123222
[TBL] [Abstract][Full Text] [Related]
14. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
15. Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study.
Noguchi T; Kobayashi J; Yagi K; Nohara A; Yamaaki N; Sugihara M; Ito N; Oka R; Kawashiri MA; Tada H; Takata M; Inazu A; Yamagishi M; Mabuchi H
Atherosclerosis; 2011 Jul; 217(1):165-70. PubMed ID: 21411093
[TBL] [Abstract][Full Text] [Related]
16. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
17. Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin/kexin type 9 levels in statin-naive patients with coronary artery disease.
Nozue T; Hattori H; Ishihara M; Iwasaki T; Hirano T; Kawashiri MA; Yamagishi M; Michishita I
Am J Cardiol; 2013 May; 111(10):1415-9. PubMed ID: 23433768
[TBL] [Abstract][Full Text] [Related]
18. Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients.
Chan DC; Hamilton SJ; Rye KA; Chew GT; Jenkins AJ; Lambert G; Watts GF
Diabetes Obes Metab; 2010 Sep; 12(9):752-6. PubMed ID: 20649626
[TBL] [Abstract][Full Text] [Related]
19. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
[TBL] [Abstract][Full Text] [Related]
20. Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system.
Poirier S; Prat A; Marcinkiewicz E; Paquin J; Chitramuthu BP; Baranowski D; Cadieux B; Bennett HP; Seidah NG
J Neurochem; 2006 Aug; 98(3):838-50. PubMed ID: 16893422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
